Results 41 to 50 of about 205,631 (301)

Planar 99mTc-PSMA Imaging of Prostate Cancer in a Low-Resource Setting: A Series Report

World Journal of Nuclear Medicine, 2022
Objective Technetium-99m labeled prostate-specific membrane antigen (PSMA) single-photon emission computed tomography/computed tomography (SPECT/CT) is a suitable alternative to prostate-specific membrane antigen-positron emission tomography (PSMA-PET ...
A.T. Orunmuyi, A.A. Oladeji, E.U. Azodoh, O.A. Omisanjo, E.O. Olapade-Olaopa   +4 more
doaj   +1 more source

Bad expression influences time to androgen escape in prostate cancer [PDF]

, 2007
<b>OBJECTIVE</b>: To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation therapy is the treatment of choice in ...
Bracarda S, Chi KN, Edwards J, Eisenmann KM, Gleave M, Huggins C, Ichinose M, Kelekar A, Lebedeva I, McDonnell TJ   +9 more
core   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo

Molecular Therapy: Nucleic Acids, 2016
The androgen receptor plays a critical role in the progression of prostate cancer. Here, we describe targeting the prostate-specific membrane antigen using a lipid nanoparticle formulation containing small interfering RNA designed to silence expression ...
Justin B Lee, Kaixin Zhang, Yuen Yi C Tam, Joslyn Quick, Ying K Tam, Paulo JC Lin, Sam Chen, Yan Liu, Jayaprakash K Nair, Ivan Zlatev, Kallanthottathil G Rajeev, Muthiah Manoharan, Paul S Rennie, Pieter R Cullis   +13 more
doaj   +1 more source

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

Nature Communications, 2023
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in lethal metastatic ...
Vipul Bhatia, Nikhil V. Kamat, Tiffany E. Pariva, Li-Ting Wu, Annabelle Tsao, Koichi Sasaki, Huiyun Sun, Gerardo Javier, Sam Nutt, Ilsa Coleman, Lauren Hitchcock, Ailin Zhang, Dmytro Rudoy, Roman Gulati, Radhika A. Patel, Martine P. Roudier, Lawrence D. True, Shivani Srivastava, Colm M. Morrissey, Michael C. Haffner, Peter S. Nelson, Saul J. Priceman, Jun Ishihara, John K. Lee   +23 more
doaj   +1 more source

Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes [PDF]

, 2007
Adhesion molecules of the integrin beta1 family are thought to be involved in the malignant progression renal cell carcinoma (RCC). Still, it is not clear how they contribute to this process.
Achiwa H, Anastassiou G, Blattner SM, Brenner W, Dufour S, Hegerfeldt Y, Hii CS, Markovic-Lipkovski J, Perlino E, Seftor RE, Yamada S   +10 more
core   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Detection rates of recurrent prostate cancer : 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review [PDF]

, 2019
Background: The aim of this work was to assess the use of prostate-specific membrane antigen (PSMA)-labelled radiotracers in detecting the recurrence of prostate cancer.
Chaplin, Brian, KandaSwamy, Gokul Vignesh, Lane, Tim, Moghul, Masood, Peedell, Clive, Rai, Bhavan Prasad, Somani, Bhaskar, Vasdev, Nikhil   +7 more
core   +2 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells [PDF]

, 2007
Upregulation of functional voltage-gated Na+ channels (VGSCs) occurs in metastatic human breast cancer (BCa) in vitro and in vivo. The present study aimed to ascertain the specific involvement of the 'neonatal' splice variant of Nav1.5 (nNav1.5), thought
Brackenbury, William J., Chioni, Athina-Myrto, Diss, James K. J., Djamgoz, Mustafa B. A.   +3 more
core   +1 more source